Nasivin Erwachsene Und Schulkinder (Oxymetazoline Hydrochloride)

Oxymetazoline is a selective alpha‑adrenergic agonist. By binding to alpha‑1 receptors on the blood vessels of the nasal mucosa, it causes vasoconstriction, which reduces swelling and opens the nasal passages, providing rapid decongestion.

The exact dosing regimen is determined by the prescribing healthcare professional. Typical OTC guidance recommends one or two sprays per nostril, not exceeding the maximum daily frequency indicated on the product label.

Safety data for oxymetazoline in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should consult their physician before using this product.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nasivin’s active ingredient, oxymetazoline, provides longer‑lasting vasoconstriction than phenylephrine, another common OTC decongestant. Oxymetazoline typically offers relief for up to 12 hours, whereas phenylephrine may require more frequent dosing, but both share similar safety considerations regarding rebound congestion.

Store Nasivin at room temperature, below 25 °C, in its original packaging. Keep the bottle tightly closed, protect it from moisture and direct sunlight, and keep it out of reach of children.

Nasivin is applied intranasally. The user gently inserts the spray tip into each nostril, inhales lightly, and actuates the pump to deliver the recommended number of sprays. The product should not be used for longer than the period indicated on the label.

Serious risks include rebound nasal congestion after prolonged use, significant increases in blood pressure, tachycardia, and rare cases of severe nasal ulceration or allergic reactions such as rash or angioedema. Users should discontinue use and seek medical attention if these events occur.

Individuals with known hypersensitivity to oxymetazoline or any formulation component, children under six years of age, patients with severe hypertension, coronary artery disease, or those taking monoamine oxidase inhibitors should avoid using this product unless directed by a physician.